Secukinumab for moderate to severe palmoplantar pustular psoriasis: Results of the 2PRECISE study

Palmoplantar pustular psoriasis is chronic, disabling and resistant to treatment. The 2PRECISE randomized controlled trial shows potential benefits of secukinumab in the treatment of palmoplantar pustular psoriasis over 52 weeks with improved quality of life, and no unexpected adverse events.

http://bit.ly/2RxhSB9